5-Fluorouracil Induced Hypertriglyceridemia During the Colorectal Cancer Treatment in a Patient With Multifactorial Chylomicronemia Syndrome: A Case Report.

5-fluorouracil Capecitabine Hypertriglyceridemia Metastatic colorectal cancer Obesity Type 2 diabetes mellitus

Journal

Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726

Informations de publication

Date de publication:
18 May 2024
Historique:
received: 05 03 2024
revised: 01 05 2024
accepted: 01 05 2024
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 19 5 2024
Statut: aheadofprint

Résumé

The case of a 47-year-old female patient who underwent sigmoidectomy for metastatic colorectal cancer is reported. Treatment with capecitabine and 5-fluorouracil induced severe hypertriglyceridemia repeatedly. Based on laboratory tests and clinical evaluations, treatment was suggested by specialists. After treatment with capecitabine, the patient's triglycerides increased from 19.7 mmol/L to 42 mmol/L. It was proposed that the patient had multifactorial chylomicronemia syndrome triggered by secondary factors. Statins, fenofibrate, ezetimib, and metformin were added to the therapy. After metastases appeared, FOLFIRI (leucovorin calcium [folinic acid], 5-fluorouracil, and irinotecan hydrochloride) chemotherapy and biological treatment (cetuximab) followed and triglycerides increased to 55.3 mmol/L. Monitoring triglyceride levels before and during therapy is suggested.

Identifiants

pubmed: 38763818
pii: S0149-2918(24)00108-5
doi: 10.1016/j.clinthera.2024.05.001
pii:
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Adela Penesova (A)

Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; Faculty of Physical Education and Sport, Comenius University, Bratislava, Slovakia. Electronic address: adela.penesova@savba.sk.

Peter Minarik (P)

Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; St. Elisabeth University of Health and Social Work in Bratislava n.o, Institute for Prevention and Intervention, Bratislava, Slovakia.

Miroslava Huckova (M)

Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Miroslav Vlcek (M)

Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia; Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.

Maria Szantova (M)

3(rd) Internal Clinic, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Olga Krizanova (O)

Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Classifications MeSH